ETI (CFTR Triple Therapy): Clinical Opportunities

https://is1-ssl.mzstatic.com/image/thumb/Podcasts112/v4/93/80/a3/9380a3e6-8135-ddbc-2128-1011bf954bd7/mza_3707003826622290779.jpeg/600x600bb.jpg

eCysticFibrosis Review

72 episodes

8 months ago

Expert insight and analysis providing information directly relevant to cystic fibrosis care, through topic-focused newsletters summarizing the peer-reviewed literature and accompanying podcasts to illustrate how to apply that information in the clinic.

Hosted on Acast. See acast.com/privacy for more information.

All content for eCysticFibrosis Review is the property of eCysticFibrosis Review and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Hosted on Acast. See acast.com/privacy for more information.

Medicine

Education,

Health & Fitness

https://assets.pippa.io/shows/5fa6e32f007fe14c6dd46501/1606931129949-7dcd8e4f19b4a46abf23069ff1fc7105.jpeg

ETI (CFTR Triple Therapy): Clinical Opportunities

eCysticFibrosis Review

28 minutes 8 seconds

3 years ago

ETI (CFTR Triple Therapy): Clinical Opportunities

The advent of triple CFTR modulator therapy – ETI (elexacaftor/tezacaftor/ivacaftor) — poses a number of clinical questions. Are three agents really better than two? For which patients, in what circumstances? What does the CF Team need to understand to ensure their patients get maximum benefit?

Join us as we explore these questions with guest author Professor Edward McKone MD, from St. Vincent’s University Hospital and University College Dublin School of Medicine, in this eCysticFibrosis Review podcast.

Take our post-test to claim CME credits.

Read this podcast's companion newsletter here.

Hosted on Acast. See acast.com/privacy for more information.